Herbal drug treatment

Neuroendocrinology Letters

Volumn 29, Issue SUPPL. 1, 2008, Pages 93-104

  Jarema, Marek ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Ginkgo biloba; Kava kava; St. John's wort; Valerian

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BUSPIRONE; DIAZEPAM; FLUOXETINE; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; KAVA EXTRACT; MAPROTILINE; OPIPRAMOL; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT; VALERIAN; VENLAFAXINE;

ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; ARTICLE; BRAIN DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION LOSS; CROCUS; CROCUS SATIVUS; DEMENTIA; DEPRESSION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEART PROTECTION; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; LAVENDER; LIVER TOXICITY; MAJOR DEPRESSION; MELISSA OFFICINALIS; MEMORY DISORDER; MENTAL DISEASE; MOOD DISORDER; MULTIINFARCT DEMENTIA; NEUROPROTECTION; PSYCHOPHARMACOLOGY; PSYCHOSIS; RECOMMENDED DRUG DOSE; RHODIOLA; RHODIOLA ROSEA; SCHIZOPHRENIA; SKIN TOXICITY; SLEEP DISORDER; SOMATOFORM DISORDER; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

CLINICAL TRIALS AS TOPIC; GINKGO BILOBA; HERBAL MEDICINE; HUMANS; HYPERICUM; KAVA; MENTAL DISORDERS; PHYTOTHERAPY; PLANT PREPARATIONS; VALERIAN;

EID: 63449138151     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Alderman CP, Kiepfer B: Complementary medicine use by psychiatry patients of an Australian hospital. Ann. Pharmacother. 2003, 37: 1779-1784.
2. Almeida JC, Grimsley EW: Coma from the health food store: an interaction between kava kava and alprazolam. Ann. Int. Med. 1996, 125: 940-941.
3. Andreatini R, Sartori VA, Seabra ML, Leite JR: Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother. Res. 2002, 16: 650-654.
4. Anke J, Ramzan I: Kava hepatotoxicity: are we any closer to the truth? Planta Med. 2004, 70, 193-196.
5. Beauburn G, Gray GE: A review of herbal medicines for psychiatric disorders. Psychiatr. Serv. 2000, 51: 1130-1134.
6. Bjerkenstedt L, Edma GV, Alken RG, Mannel M: Hypericum extract LI160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255: 40-47.
7. Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M: Kava-kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder - an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomed. 2003, 10, suppl. 4:38-49.
8. Briks J, Grimley EJ: Ginkgo biloba for cognitive impairment in dementia. Cochrane Database Syst. Rev. 2007, CD003120.
9. Brockmöller J, Reum T, Bauer S, Kerb R, Hübner WD, Roots I: Hypericin and psyeudohypericin: pjarmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry, 1997, 30: suppl. 2, 94-101.
10. Canter PH, Ernst E: Ginkgo biloba is not a smart drug: an updated systematic review of randomized clinical trials testing the nootropic effect of g.biloba extracts in healthy people. Hum. Psychopharmacol. 2007, 22: 265-278.
11. Carlson JJ, Farquhar JW, DiNucci E, Ausserer L, Zehnder J, Miller D, Berra K, Hagerty L, Haskell WL: Safety and efficacy of a gingko biloba-containing dietary supplement on cognitive function, quality of life, and platelet function in healthy, cognitively intact older adults. J. Am. Diet. Ass. 2007, 107: 422-432.
12. Chan PC, Xia Q, Fu PP: Ginko biloba leave extract: biological, medicinal, and toxicological effects. J. Envirin. Sci. Health C. Envirin. Carcinog. Ecotoxicol. Rev. 2007, 25: 211-214.
13. Connor KM, Payne V, Davidson JR: Kava in generalized anxiety disorder: three placebo-controlled trials. Int. Clin. Psychopharmacol. 2006, 21: 249-253.
14. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF: A double-blind, randomized trial of St. John's wort, fluoxetine, and placebo in major depressive disorder. J. Clin. Psychopharmacol. 2005, 25: 441-447.
15. Gaster B, Holyroyd J: St. John's wort for depression: a systematic review. Arch. Int. Med. 2000, 160, 152-156.
16. Grounder R: Kava consumption and its health effects. Pac. Health Dialog. 2006, 13: 131-135.
17. Jacobs BP, Bent S, Tice JA, Blackwell T, Cummings SR: An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine, 2005, 84: 197-207.
18. Kalus P, Strik WK: Phytoterapeuthic drugs in psychiatry. Ther. Umsch. 2002, 59: 307-312.
19. Kim HL, Streltzer J, Goebert D: St. John's wort for depression: a meta-analysis of well-defined clinical trials. J. Nerv. Ment. Dis. 1999, 187: 532-539.
20. Kleijnen J, Knipschild P: Ginkgo biloba. Lancet, 1992, 340: 1136-1139.
21. Lake J: Psychotropic medications from natural products: a review of promising research and recommendations. Altern. Ther. Health Med. 2000, 6: 39-45.
22. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA, 1997, 278: 1327-1332.
23. Le Bars PL, Velasco FM, Ferguson JM, Dessian EC, Kieser M, Hoerr R: Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology, 2002, 45: 19-26.
24. Linde K, Ramirez G, Murlow CD, Paulus A, Weidenhammer W, Melchart D: St John's wort for depression - an overview and meta-analysis of randomized clinical trials. BMJ, 1996, 313: 253-258.
25. Linde K, Murlow CD, Berner M, Egger M: St John's wort for depression. Cochrane Database Syst. Rev 2, 2005, CD000448
26. Mahadevan S, Park Y: Multifaceted therapeutic benefits of Ginco biloba L: chemistry, efficacy, safety, and use. J. Food Sci. 2008, 73: R14-R19.
27. Marinac JS, Buchinger CL, Godfrey LA, Wooten JM, Sun C, Willsie SK: Herbal products and dietary supplements: a syrvey of use, attitudes, and knowledge among older adults. J. Am. Osteopath. Assoc. 2007, 107: 13-20.
28. Meston CM, Rellini AH, Telch MJ: Short- and ling-term effects of Ginkgo biloba extract on sexual dysfunction in women. Arch. Sex. Behav. 2008, 4: 530-547.
29. Miller LG: Herbal medicines: selected clinical considerations focusing on known or potential drug-herb interactions. Arch. Int. Med. 1998, 158: 2200-2209.
30. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur. J. Clin. Pharmacol. 2006, 62: 29-36.
31. Napryeyenko O, Borzenko I, GINDEM-NP Study Group: Gingko biloba special extract in dementia with neuropsychitric future. A randomized, placebo-controlled, double-blind clinical trial. Arzneimitterforschung, 2007, 57: 4-11.
32. Ramassamy C, Longpre F, Christen Y: Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence? Curr. Alzheimer Res. 2007, 4: 253-262.
33. Roder C, Schaefer M. Leucht S: Meta-Analyse zu Wirksamkeit und Verträglichkeit der Behandlung der leichten und mittelschweren Depression mit Johanniskraut. Fortschr. Neurol. Psychiatr. 2004, 7: 330-343.
34. Saeed SA, Bloch RM, Anotacci DJ: Herbal and dietary supplements for treatment of anxiety disorders. Am. Fam. Physician, 2007, 76: 549-556.
35. Sarris J: Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytother. Res. 2007, 21: 703-716.
36. Stevinson C, Huntley A, Ernst E: A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf. 2002, 25: 251-261.
37. Tasman A, Kay JD, Lieberman JA: Psychiatry, Second Edition. CAM treatments. Wiley, 2000.
38. van de Watt G, Laugharne J, Janca A: Complementary and alternative medicine in the treatment of anxiety and depression. Curr Opin Psychiatry. 2008 Jan; 21(1):37-42.
39. Vorbach EU, Arnoldt KH, Hubner WD: Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacop[sychiatry, 1997, 30, suppl. 2: 81-85.
40. Walter G, rey JM: The relevance of herbal treatments for psychiatric practice. Aust. N. Zel. J. Psychiatry, 1999, 33: 482-489.
41. Wheatley D: Stress-induced insomnia treated with kava and valerian: singly and in combination. Hum. Psychopharmacol. 2001, 16: 353-356.
42. Witte S, Loew D, GHaus W: Meta-analysis of the efficacy of the acetonic kava-kava extract WS 1490 in patients wint non-psychotic anxiety disorders. Phytother. Res. 2005, 19: 183-188.
43. Woelk H, Burkard G, Grunwald J: Benefits and risks of the hypericum extract LI 160 drug monitoring study with 3,250 patients. J. Geriatr. Psychiatry Neurol. 1994, 7, suppl. 1: 34-38.
44. Woelk H, Arnoldt KH, Kieser M, Hoerr R: Ginko biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized double-blind, placebo-controlled trial. J. Psychiatr. Res. 2007, 41: 472-480.
45. Wong AH, Smith M, Boon HS: Herbal remedies in psychiatric practice. Arch. Gen. Psychiatry, 1998, 55: 1033-1043.
46. Wu Y, Li S, Cui W, Zu X, Du J, Wang F: Ginkgo biloba extract improves coronary blood flow in healthy elderly adults: role of endothelium-dependent vasodilatation. Phytomed. 2008, 15: 164-169.